The biopharmaceutical company had a stockpile of 12 patents and research crafted by Pilot founder Dr. Floyd H. Chilton at Wake Forest University. The company also had a focus on specific nutraceuticals, which currently do not require lengthy U.S. Food and Drug Administration review because they are naturally occurring bioactive lipids. For a biotechnology company to have products in such a short time frame in unusual, said Dr. Kenneth M. Tramposch, the company s executive vice president and chief operating officer. Since its formation, Pilot has quickly become a venture-backed company that is developing proprietary nutraceutical and pharmaceutical products for inflammatory and proliferative diseases, including asthma, allergic rhinitis, arthritis and cancer.
Bioactive lipids are key structural and functional components of the human body.
It is now known that the misregulation of bioactive lipids is a significant cause of chronic disease. Pilot s products are designed to normalize the regulation of bioactive lipids in the body for therapeutic benefit. Pilot s initial products are essentially dietary supplements, branded Ethical Nutraceuticals TM . Dietary supplements include vitamins, minerals, herbs, botanicals, and other plant-derived substances, amino acids, and concentrates, metabolites, constituents, and extracts of these substances. Ethical Nutraceuticals TM are patent-protected dietary supplements supported by vigorous internal clinical trials that demonstrate safety and efficacy.